CL2015001754A1 - Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo. - Google Patents
Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo.Info
- Publication number
- CL2015001754A1 CL2015001754A1 CL2015001754A CL2015001754A CL2015001754A1 CL 2015001754 A1 CL2015001754 A1 CL 2015001754A1 CL 2015001754 A CL2015001754 A CL 2015001754A CL 2015001754 A CL2015001754 A CL 2015001754A CL 2015001754 A1 CL2015001754 A1 CL 2015001754A1
- Authority
- CL
- Chile
- Prior art keywords
- retinal
- lipofuscin
- isoquinoline
- vegf
- quinoline
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 208000017442 Retinal disease Diseases 0.000 title 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 238000009825 accumulation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000011506 response to oxidative stress Effects 0.000 title 1
- 230000002207 retinal effect Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740197P | 2012-12-20 | 2012-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015001754A1 true CL2015001754A1 (es) | 2015-11-06 |
Family
ID=50979217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015001754A CL2015001754A1 (es) | 2012-12-20 | 2015-06-18 | Compuestos derivados de quinolina e isoquinolina; composición farmacéutica y uso para reducir el riesgo de desarrollar una enfermedad o trastorno retinal en el que la acumulación de a2e y/o lipofuscina en el tejido retinal o la señalización de vegf de las células rpe en respuesta al estrés oxidativo. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9604997B2 (2) |
| EP (1) | EP2935220A4 (2) |
| JP (1) | JP2016503797A (2) |
| KR (1) | KR20150118106A (2) |
| CN (1) | CN105073714A (2) |
| AU (1) | AU2013361314A1 (2) |
| CA (1) | CA2896032A1 (2) |
| CL (1) | CL2015001754A1 (2) |
| HK (1) | HK1217325A1 (2) |
| IL (1) | IL239178A0 (2) |
| MX (1) | MX2015007916A (2) |
| RU (1) | RU2015120478A (2) |
| SG (1) | SG11201504859YA (2) |
| WO (1) | WO2014100425A1 (2) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485753B2 (en) | 2012-12-21 | 2022-11-01 | Janssen Pharmaceutica Nv | Substituted nucleosides, nucleotides and analogs thereof |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| HK1217490A1 (zh) | 2013-01-25 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 黃斑變性治療中的新穎捕獲劑 |
| CN108135907A (zh) | 2015-08-21 | 2018-06-08 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| BR112018003264A2 (pt) * | 2015-08-21 | 2018-09-25 | Aldeyra Therapeutics Inc | conjugados de aldeído e usos dos mesmos |
| MX2018010292A (es) | 2016-02-28 | 2018-09-27 | Aldeyra Therapeutics Inc | Tratamiento de condiciones oculares alergicas con ciclodextrinas. |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| CN109640983A (zh) * | 2016-08-22 | 2019-04-16 | 奥尔德拉医疗公司 | 醛捕获化合物和其用途 |
| US10414732B2 (en) | 2017-03-16 | 2019-09-17 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| JP7505786B2 (ja) | 2018-09-25 | 2024-06-25 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
| WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| MX2023000263A (es) | 2020-07-16 | 2023-03-29 | Dermavant Sciences GmbH | Compuestos isoquinolina y su uso en el tratamiento del desequilibrio de ahr. |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| CA2054339C (en) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | 3-amidoindolyl derivatives |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| WO1998005645A1 (en) | 1996-08-01 | 1998-02-12 | Dow Agrosciences Llc | 4-substituted quinoline derivatives having fungicidal activity |
| EP0980362B1 (de) | 1997-05-02 | 2006-08-16 | Schering Aktiengesellschaft | Substituierte heterocyclen und deren verwendung in arzneimitteln |
| EP1080068A1 (en) | 1998-03-12 | 2001-03-07 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| WO2001041757A1 (en) | 1999-12-10 | 2001-06-14 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US20040242704A1 (en) | 2003-03-14 | 2004-12-02 | University Of Washington, Techtransfer - Invention Licensing | Stabilized mutant opsin proteins |
| EP2292239A3 (en) | 2003-04-18 | 2011-03-30 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
| AU2004293105B2 (en) | 2003-11-20 | 2010-09-09 | Othera Holding, Inc. | Amelioration of macular degeneration and other ophthalmic diseases |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| AU2005215778B2 (en) | 2004-02-17 | 2009-03-12 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| WO2006002473A1 (en) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Method of controlling damage mediated by alpha, beta-unsaturated aldehydes |
| US20070287716A1 (en) * | 2004-10-28 | 2007-12-13 | Hu Essa H | Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| EP2336117A1 (en) | 2005-05-26 | 2011-06-22 | Neuron Systems, Inc | Heterocyclic compounds for treating retinal diseases |
| BRPI0722382A2 (pt) * | 2006-04-14 | 2012-06-05 | Prana Biotechnology Ltd | compostos úteis para o tratamento de cáncer |
| CA2658793A1 (en) * | 2006-07-25 | 2008-02-07 | Daniel Dumas | Quinoline derivatives |
| TW200922548A (en) | 2007-10-05 | 2009-06-01 | Acucela Inc | Alkoxy compounds for disease treatment |
| WO2010019606A1 (en) | 2008-08-12 | 2010-02-18 | Sirtris Pharmaceuticals, Inc. | Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators |
| WO2010133672A1 (en) * | 2009-05-20 | 2010-11-25 | Clanotech Ab | Derivatives of quinoline-3-carboxylic acid and their medical use |
| WO2011008202A1 (en) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Isoketal scavengers and mitigation of disorders involving oxidative injury |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2824779C (en) | 2011-01-12 | 2020-01-14 | Array Biopharma, Inc. | Substituted benzoazepines as toll-like receptor modulators |
| EP2670439B1 (en) | 2011-01-31 | 2019-03-13 | PVAC Medical Technologies Ltd. | Active principle for mitigating undesired medical conditions |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| HK1217490A1 (zh) | 2013-01-25 | 2017-01-13 | Aldeyra Therapeutics, Inc. | 黃斑變性治療中的新穎捕獲劑 |
| EP3151818A4 (en) | 2014-06-04 | 2018-05-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
| US10363231B2 (en) | 2014-11-24 | 2019-07-30 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
-
2013
- 2013-12-19 HK HK16105238.3A patent/HK1217325A1/zh unknown
- 2013-12-19 CN CN201380067618.3A patent/CN105073714A/zh active Pending
- 2013-12-19 EP EP13865015.5A patent/EP2935220A4/en not_active Withdrawn
- 2013-12-19 JP JP2015549717A patent/JP2016503797A/ja not_active Withdrawn
- 2013-12-19 AU AU2013361314A patent/AU2013361314A1/en not_active Abandoned
- 2013-12-19 WO PCT/US2013/076592 patent/WO2014100425A1/en not_active Ceased
- 2013-12-19 RU RU2015120478A patent/RU2015120478A/ru unknown
- 2013-12-19 KR KR1020157019397A patent/KR20150118106A/ko not_active Withdrawn
- 2013-12-19 MX MX2015007916A patent/MX2015007916A/es unknown
- 2013-12-19 US US14/653,771 patent/US9604997B2/en active Active
- 2013-12-19 CA CA2896032A patent/CA2896032A1/en not_active Abandoned
- 2013-12-19 SG SG11201504859YA patent/SG11201504859YA/en unknown
-
2015
- 2015-06-03 IL IL239178A patent/IL239178A0/en unknown
- 2015-06-18 CL CL2015001754A patent/CL2015001754A1/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11485753B2 (en) | 2012-12-21 | 2022-11-01 | Janssen Pharmaceutica Nv | Substituted nucleosides, nucleotides and analogs thereof |
| US12173025B2 (en) | 2012-12-21 | 2024-12-24 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201504859YA (en) | 2015-07-30 |
| RU2015120478A (ru) | 2017-01-25 |
| HK1217325A1 (zh) | 2017-01-06 |
| MX2015007916A (es) | 2016-04-07 |
| US9604997B2 (en) | 2017-03-28 |
| EP2935220A4 (en) | 2016-04-27 |
| CN105073714A (zh) | 2015-11-18 |
| AU2013361314A1 (en) | 2015-07-02 |
| CA2896032A1 (en) | 2014-06-26 |
| US20150344432A1 (en) | 2015-12-03 |
| WO2014100425A1 (en) | 2014-06-26 |
| EP2935220A1 (en) | 2015-10-28 |
| JP2016503797A (ja) | 2016-02-08 |
| IL239178A0 (en) | 2015-07-30 |
| KR20150118106A (ko) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE053113T2 (hu) | Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra | |
| CL2014003619A1 (es) | Jeringa prellenada que comprende una solución de un antagonista de vegf; empaque blister; uso de la jeringa para tratar enfermedades oculares. | |
| BR112015003376A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente | |
| PT2877184T (pt) | Composições e tratamento para doenças e distúrbios oculares | |
| FR2994387B1 (fr) | Ingredient hydratant cosmetique ou pharmaceutique | |
| EP2817061A4 (en) | IMPROVED ABLATION TECHNIQUES FOR THE TREATMENT OF PREVIOUS LAYOUMS | |
| BR112013023174A2 (pt) | "compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos" | |
| EP2922877A4 (en) | IMPROVED PEPTIDATE MEDICINES | |
| BR302012004277S1 (pt) | "configuração aplicada à cápsula" | |
| EP2838549A4 (en) | MEDICINAL PRODUCT FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FAT TEMPERATURE DISEASE | |
| EP2842945A4 (en) | SULFONAMIDE DERIVATIVE AND MEDICAL USE THEREOF | |
| IL229017B (en) | Oxidative retinal diseases | |
| UA24447S (uk) | М'ясорубка | |
| BR302012004271S1 (pt) | "configuração aplicada à cápsula" | |
| EP2827866A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH BENZYL ALCOHOL | |
| HUE037673T2 (hu) | Szulfonil-piperidin-származékok és alkalmazásuk prokineticin-mediált betegségek kezelésére | |
| BR302012004276S1 (pt) | "configuração aplicada à cápsula" | |
| BR112014016389A8 (pt) | composições e uso das mesmas para o tratamento de distúrbios e doenças hepáticas | |
| EP3009426A4 (en) | 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICAMENT THEREFORE AS AN ACTIVE SUBSTANCE | |
| BR302012004275S1 (pt) | "configuração aplicada à cápsula" | |
| MX374468B (es) | Composicion farmaceutica acuosa semisolida que contiene tapentadol. | |
| PL2922576T3 (pl) | Sposoby podawania i oceny leków wychwytujących azot do leczenia encefalopati wątrobowej | |
| PT2706062T (pt) | Novos derivados da cefalosporina e sua composição farmacêutica | |
| EP2872155A4 (en) | BIOMATERIALS FOR IMPROVED IMPLANT HOST INTEGRATION | |
| CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. |